Segall Bryant & Hamill LLC Purchases 52,454 Shares of Horizon Pharma PLC (HZNP)

Segall Bryant & Hamill LLC boosted its position in Horizon Pharma PLC (NASDAQ:HZNP) by 8.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 643,928 shares of the biopharmaceutical company’s stock after buying an additional 52,454 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.39% of Horizon Pharma worth $8,165,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Sheaff Brock Investment Advisors LLC boosted its position in Horizon Pharma by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 500 shares during the last quarter. Prudential Financial Inc. boosted its position in Horizon Pharma by 5.0% in the second quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 830 shares during the last quarter. Amalgamated Bank boosted its position in Horizon Pharma by 4.8% in the second quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 943 shares during the last quarter. Bank of Montreal Can boosted its position in Horizon Pharma by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,378 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Horizon Pharma by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock valued at $1,495,000 after buying an additional 1,379 shares during the last quarter. Hedge funds and other institutional investors own 86.59% of the company’s stock.

Horizon Pharma PLC (NASDAQ HZNP) opened at $14.90 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The firm has a market capitalization of $2,450.00, a P/E ratio of 10.49, a PEG ratio of 1.23 and a beta of 1.31. Horizon Pharma PLC has a 52 week low of $9.45 and a 52 week high of $18.31.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.04. The business had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The business’s quarterly revenue was up 30.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.70 EPS. research analysts anticipate that Horizon Pharma PLC will post 0.72 earnings per share for the current year.

Several research firms have commented on HZNP. Piper Jaffray Companies set a $18.00 price objective on Horizon Pharma and gave the stock a “buy” rating in a research report on Sunday, September 10th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of Horizon Pharma in a research report on Sunday, October 22nd. ValuEngine upgraded Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Monday, October 16th. Cowen restated a “buy” rating on shares of Horizon Pharma in a research report on Thursday, September 28th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $17.00 price objective on shares of Horizon Pharma in a research report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the stock. Horizon Pharma has a consensus rating of “Buy” and an average target price of $18.75.

ILLEGAL ACTIVITY NOTICE: “Segall Bryant & Hamill LLC Purchases 52,454 Shares of Horizon Pharma PLC (HZNP)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/12/09/segall-bryant-hamill-llc-purchases-52454-shares-of-horizon-pharma-plc-hznp.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply